BioCentury
ARTICLE | Financial News

Peloton planning Phase III kidney cancer study with $150M series E

February 22, 2019 7:10 PM UTC

With the proceeds of its new $150 million series E round, Peloton Therapeutics Inc. (Dallas, Texas) plans to start a Phase III trial next half of lead candidate PT2977 to treat advanced renal cell carcinoma (RCC). The therapy is an oral inhibitor of endothelial PAS domain protein 1 (HIF2A; HIF-2α; EPAS1).

RA Capital led the series E round, announced Feb. 20...